FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4230582020> ?p ?o ?g. }

• W4230582020 endingPage "751" @default.
• W4230582020 startingPage "745" @default.
• W4230582020 abstract "OBJECTIVE To determine whether fibroblast growth factor 23 (FGF23) concentrations are altered in women with ovarian cancers in which FGF physiology is known to be abnormal. PATIENTS AND METHODS Between May 2002 and September 2003 at the Mayo Clinic in Rochester, Minn, plasma or serum FGF23 concentrations were measured in 39 healthy women and in 14 with benign ovarian tumors, 14 with early-stage ovarian cancer, and 13 with advanced-stage ovarian cancer. Immunohistochemistry using anti-human FGF23 antibodies was performed on tissue from benign masses and advanced-stage tumors. RESULTS Serum or plasma FGF23 concentrations were significantly higher in women with advanced-stage ovarian cancer compared with concentrations in women with early-stage ovarian cancer or benign disease or in healthy women. A significant positive correlation was seen between serum iFGF23 and cFGF23 concentrations and stage of disease. Serum iFGF23 and cFGF23 concentrations were positively correlated with serum phosphorus among women with ovarian cancer. No patients with elevated iFGF23 or cFGF23 concentrations had hypophosphatemia. Immunohistochemistry detected FGF23 tissue staining in malignant ovarian cancer cells. CONCLUSION Serum or plasma FGF23 concentrations are elevated in patients with advanced-stage epithelial ovarian cancer without reductions in serum phosphate concentrations. The presence of elevated FGF23 concentrations in patients with an ovarian mass should suggest advanced-stage disease. To determine whether fibroblast growth factor 23 (FGF23) concentrations are altered in women with ovarian cancers in which FGF physiology is known to be abnormal. Between May 2002 and September 2003 at the Mayo Clinic in Rochester, Minn, plasma or serum FGF23 concentrations were measured in 39 healthy women and in 14 with benign ovarian tumors, 14 with early-stage ovarian cancer, and 13 with advanced-stage ovarian cancer. Immunohistochemistry using anti-human FGF23 antibodies was performed on tissue from benign masses and advanced-stage tumors. Serum or plasma FGF23 concentrations were significantly higher in women with advanced-stage ovarian cancer compared with concentrations in women with early-stage ovarian cancer or benign disease or in healthy women. A significant positive correlation was seen between serum iFGF23 and cFGF23 concentrations and stage of disease. Serum iFGF23 and cFGF23 concentrations were positively correlated with serum phosphorus among women with ovarian cancer. No patients with elevated iFGF23 or cFGF23 concentrations had hypophosphatemia. Immunohistochemistry detected FGF23 tissue staining in malignant ovarian cancer cells. Serum or plasma FGF23 concentrations are elevated in patients with advanced-stage epithelial ovarian cancer without reductions in serum phosphate concentrations. The presence of elevated FGF23 concentrations in patients with an ovarian mass should suggest advanced-stage disease." @default.
• W4230582020 created "2022-05-11" @default.
• W4230582020 creator A5002879004 @default.
• W4230582020 creator A5005798440 @default.
• W4230582020 creator A5056265052 @default.
• W4230582020 creator A5063258499 @default.
• W4230582020 creator A5065524254 @default.
• W4230582020 creator A5067520596 @default.
• W4230582020 creator A5079731206 @default.
• W4230582020 date "2005-06-01" @default.
• W4230582020 modified "2023-10-16" @default.
• W4230582020 title "Elevated Fibroblast Growth Factor 23 in Women With Malignant Ovarian Tumors" @default.
• W4230582020 cites W1548852974 @default.
• W4230582020 cites W1968642368 @default.
• W4230582020 cites W1968779137 @default.
• W4230582020 cites W1970305413 @default.
• W4230582020 cites W1970357063 @default.
• W4230582020 cites W1973380233 @default.
• W4230582020 cites W1974025321 @default.
• W4230582020 cites W1980843267 @default.
• W4230582020 cites W1991896508 @default.
• W4230582020 cites W1992568192 @default.
• W4230582020 cites W1998100845 @default.
• W4230582020 cites W2001797845 @default.
• W4230582020 cites W2002494594 @default.
• W4230582020 cites W2003490678 @default.
• W4230582020 cites W2006822593 @default.
• W4230582020 cites W2012468269 @default.
• W4230582020 cites W2022822336 @default.
• W4230582020 cites W2033081546 @default.
• W4230582020 cites W2042639382 @default.
• W4230582020 cites W2043588093 @default.
• W4230582020 cites W2044154722 @default.
• W4230582020 cites W2045129957 @default.
• W4230582020 cites W2053513870 @default.
• W4230582020 cites W2060097114 @default.
• W4230582020 cites W2068226571 @default.
• W4230582020 cites W2070913775 @default.
• W4230582020 cites W2071603947 @default.
• W4230582020 cites W2073578085 @default.
• W4230582020 cites W2081749358 @default.
• W4230582020 cites W2094262605 @default.
• W4230582020 cites W2098549085 @default.
• W4230582020 cites W2098923144 @default.
• W4230582020 cites W2105735476 @default.
• W4230582020 cites W2106503825 @default.
• W4230582020 cites W2108469980 @default.
• W4230582020 cites W2117208320 @default.
• W4230582020 cites W2123291635 @default.
• W4230582020 cites W2128059069 @default.
• W4230582020 cites W2133856372 @default.
• W4230582020 cites W2134389439 @default.
• W4230582020 cites W2141482249 @default.
• W4230582020 cites W2146828765 @default.
• W4230582020 cites W2147017270 @default.
• W4230582020 cites W2151298488 @default.
• W4230582020 cites W2164952534 @default.
• W4230582020 cites W2291615309 @default.
• W4230582020 cites W2328703921 @default.
• W4230582020 cites W4245958271 @default.
• W4230582020 cites W4255462147 @default.
• W4230582020 doi "https://doi.org/10.4065/80.6.745" @default.
• W4230582020 hasPublicationYear "2005" @default.
• W4230582020 type Work @default.
• W4230582020 citedByCount "4" @default.
• W4230582020 countsByYear W42305820202022 @default.
• W4230582020 countsByYear W42305820202023 @default.
• W4230582020 crossrefType "journal-article" @default.
• W4230582020 hasAuthorship W4230582020A5002879004 @default.
• W4230582020 hasAuthorship W4230582020A5005798440 @default.
• W4230582020 hasAuthorship W4230582020A5056265052 @default.
• W4230582020 hasAuthorship W4230582020A5063258499 @default.
• W4230582020 hasAuthorship W4230582020A5065524254 @default.
• W4230582020 hasAuthorship W4230582020A5067520596 @default.
• W4230582020 hasAuthorship W4230582020A5079731206 @default.
• W4230582020 hasConcept C114276007 @default.
• W4230582020 hasConcept C121608353 @default.
• W4230582020 hasConcept C126322002 @default.
• W4230582020 hasConcept C134018914 @default.
• W4230582020 hasConcept C146357865 @default.
• W4230582020 hasConcept C151730666 @default.
• W4230582020 hasConcept C170493617 @default.
• W4230582020 hasConcept C204232928 @default.
• W4230582020 hasConcept C2778573388 @default.
• W4230582020 hasConcept C2780427987 @default.
• W4230582020 hasConcept C2781208988 @default.
• W4230582020 hasConcept C519063684 @default.
• W4230582020 hasConcept C71924100 @default.
• W4230582020 hasConcept C74373430 @default.
• W4230582020 hasConcept C86803240 @default.
• W4230582020 hasConceptScore W4230582020C114276007 @default.
• W4230582020 hasConceptScore W4230582020C121608353 @default.
• W4230582020 hasConceptScore W4230582020C126322002 @default.
• W4230582020 hasConceptScore W4230582020C134018914 @default.
• W4230582020 hasConceptScore W4230582020C146357865 @default.
• W4230582020 hasConceptScore W4230582020C151730666 @default.
• W4230582020 hasConceptScore W4230582020C170493617 @default.
• W4230582020 hasConceptScore W4230582020C204232928 @default.

• next